Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
41 hedge funds and large institutions have $2.08M invested in Iterum Therapeutics in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 7 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.8% less ownership
Funds ownership: 3.59% → 2.79% (-0.8%)
7% less funds holding
Funds holding: 44 → 41 (-3)
19% less capital invested
Capital invested by funds: $2.57M → $2.08M (-$490K)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$22.7K |
| 2 |
Morgan Stanley
New York
|
+$12.1K |
| 3 |
GC
Grimes & Company
Westborough,
Massachusetts
|
+$11.3K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$11.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$447K |
| 2 |
VF
Virtu Financial
New York
|
-$52.2K |
| 3 |
Jane Street
New York
|
-$52K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$32K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$15K |
ITRM Hedge Fund Activity: Q1 2022 in Review
41 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Iterum Therapeutics (ITRM) for Q1 2022, worth a combined $2.08M — down 19% from $2.57M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ITRM and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Geode Capital Management, adding an estimated $22.7K. The largest seller was Anson Funds Management, exiting entirely with an estimated $447K sold.
- 41 institutional investors held Iterum Therapeutics (ITRM) as of Q1 2022, down from 44 in Q4 2021.
- Funds reported $2.08M of Iterum Therapeutics stock for Q1 2022, down 19% quarter-over-quarter.
- 4 funds opened new Iterum Therapeutics positions in Q1 2022 and 7 closed out, a net change of -3 holders.
- The largest Iterum Therapeutics buyer in Q1 2022 was Geode Capital Management, an estimated $22.7K added.
- The largest Iterum Therapeutics seller in Q1 2022 was Anson Funds Management, an estimated $447K sold.
Based on aggregated 13F filings for Q1 2022.